Canada Markets closed

RepliCel Life Sciences Inc. (RP.V)

TSXV - TSXV Real Time Price. Currency in CAD
Add to watchlist
0.38000.0000 (0.00%)
At close: 2:17PM EDT
Full screen
Previous Close0.3800
Open0.3500
Bid0.3400 x 0
Ask0.3750 x 0
Day's Range0.3450 - 0.3800
52 Week Range0.1000 - 0.5800
Volume24,000
Avg. Volume11,369
Market Cap14.079M
Beta (5Y Monthly)0.77
PE Ratio (TTM)N/A
EPS (TTM)-0.0900
Earnings DateNov. 27, 2015 - Nov. 30, 2015
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • RepliCel Applies for Manufacturing Approval for Its Collagen and Tissue Regeneration Cell Therapies
    ACCESSWIRE

    RepliCel Applies for Manufacturing Approval for Its Collagen and Tissue Regeneration Cell Therapies

    Clinical development of RepliCel's skin rejuvenation and tendon regeneration injectables continues to meet milestones on path to commercialization in JapanVANCOUVER, BC / ACCESSWIRE / July 7, 2021 / RepliCel Life Sciences Inc. (OTC PINK:REPCF)(TSXV:RP)(FSE:P6P2) ("RepliCel" or the "Company"), a company developing next-generation technologies in aesthetics and orthopedics, is pleased to announce it has submitted its application to Japan's Ministry of Health, Labour, and Welfare (MHLW) for approva

  • RepliCel Adds Independent Director
    ACCESSWIRE

    RepliCel Adds Independent Director

    Board of Directors Strengthens Its Independence Oversight and Updates its Stock Options VANCOUVER, BC / ACCESSWIRE / June 15, 2021 / RepliCel Life Sciences Inc. (OTCQB:REPCF)(TSXV:RP)(FRA:P6P2), (“RepliCel” or the “Company”), a company developing next-generation technologies in aesthetics and orthopedics, is pleased to announce it has appointed Gary Boddington to the board of directors.

  • RepliCel Launches Testing of Dermal Injector Units
    ACCESSWIRE

    RepliCel Launches Testing of Dermal Injector Units

    Initial units delivered and first phase of functional testing nearly completeVANCOUVER, BC / ACCESSWIRE / May 25, 2021 / RepliCel Life Sciences Inc.V:RP) (OTCPK:REPCF) (FRA:P6P2) ("RepliCel" or the "Company"), a company developing next-generation technologies in aesthetics and orthopedics, is pleased to announce that it has received the first units of its dermal injector and is nearing completion of the preliminary phase of functional testing required to launch executing on the larger-scale production and testing plan.